Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile
Open Access
- 27 July 2017
- journal article
- research article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 119 (2) , 211-220
Abstract
Background. Dexmedetomidine, a selective α2-adrenoreceptor agonist, has unique characteristics, with little respiratory depression and rousability during sedations. We characterized the haemodynamic properties of dexmedetomidine by developing a pharmacokinetic–pharmacodynamic (PKPD) model with a focus on changes in mean arterial blood pressure (MAP) and heart rate. Methods. Dexmedetomidine was delivered i.v. to 18 healthy volunteers in a step-up fashion by target-controlled infusion using the Dyck model. Exploratory PKPD modelling and covariate analysis were conducted in NONMEM. Results. Our model adequately describes dexmedetomidine-induced hypotension, hypertension, and bradycardia, with a greater effective concentration for the hypertensive effect. Changes in MAP were best described by a double-sigmoidal Emax model with hysteresis. Covariate analysis revealed no significant covariates apart from age on the baseline MAP in the population pharmacokinetic model used to develop this PKPD model. Simulations revealed good general agreement with published descriptive studies of haemodynamics after dexmedetomedine infusion. Conclusions. The present integrated PKPD model should allow tighter control over the desired level of sedation, while limiting potential haemodynamic side-effects. Clinical trial registration. NCT01879865.Keywords
This publication has 16 references indexed in Scilit:
- Dexmedetomidine pharmacokinetic–pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedationBritish Journal of Anaesthesia, 2017
- Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjectsEuropean Journal of Clinical Pharmacology, 2015
- Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy VolunteersAnesthesiology, 2015
- Dexmedetomidine hemodynamics in children after cardiac surgeryPediatric Anesthesia, 2010
- Effects of Low and High Plasma Concentrations of Dexmedetomidine on Myocardial Perfusion and Cardiac Function in Healthy Male SubjectsAnesthesiology, 2006
- Systemically Administered α2-Agonist-induced Peripheral Vasoconstriction in HumansAnesthesiology, 2003
- Clonidine‐induced nitric oxide‐dependent vasorelaxation mediated by endothelial α2‐adrenoceptor activationBritish Journal of Pharmacology, 2001
- The Effects of Increasing Plasma Concentrations of Dexmedetomidine in HumansAnesthesiology, 2000
- The Pharmacokinetics and Hemodynamic Effects of Intravenous and Intramuscular Dexmedetomidine Hydrochloride in Adult Human VolunteersAnesthesiology, 1993
- Effects of Intravenous Dexmedetomidine in HumansAnesthesiology, 1992